NeuroTrials Research Joins Nationwide Alzheimer's Study

A large national study is being conducted on an Alzheimer's drug candidate, and Atlanta-based NeuroTrials Research Inc. is the only trial site in Georgia currently enrolling patients. Dr. Michael Lacey serves as the study's primary investigator.

NeuroTrials is one of 50 locations across the United States participating in the NOBLE Study, a Phase-2 randomized, double blind, placebo controlled study on the potential of T-817MA, a neuroprotectant agent designed to protect against neuron loss. Neuroprotectants are used for central nervous system disorders including stroke and Parkinson's disease, but the NOBLE study is focusing on men and women with mild to moderate Alzheimer's disease.

A drug like the one being tested, which slows the progression of the disease rather than treating symptoms like other available treatments, has not been approved by the U.S. Food and Drug Administration since 2003.The study will enroll 450 people with mild to moderate Alzheimer's. Participants must be between the ages of 55 and 85, living in a community and not a nursing home, weigh no more than 220 pounds and have a study partner with at least 10 hours of contact per week. The must also have been on one of two Alzheimer's treatments, donepezil or rivastigimine, for at least six months.

Participants will be treated for about 14 months. For more information on the study & to see if someone you know may qualify, visit our study page.

Other trial sites include Georgetown University, Mount Sinai School of Medicine, Princeton University's Medical Institute and Columbia University.

Read the full article.